Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.91 USD | -1.00% |
|
-9.50% | -40.96% |
Capitalization | 1.42B 1.35B 1.27B 1.12B 2.01B 123B 2.23B 15.13B 5.61B 51.28B 5.31B 5.2B 215B | P/E ratio 2024 * |
-4.01x | P/E ratio 2025 * | -3.7x |
---|---|---|---|---|---|
Enterprise value | 800M 761M 718M 634M 1.13B 69.27B 1.26B 8.55B 3.17B 28.97B 3B 2.94B 122B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | - |
Free-Float |
98.81% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Dyne Therapeutics, Inc.
1 day | -1.00% | ||
1 week | -9.50% | ||
Current month | -2.18% | ||
1 month | -7.27% | ||
3 months | -54.11% | ||
6 months | -68.30% | ||
Current year | -40.96% |







Director | Title | Age | Since |
---|---|---|---|
John Cox
CEO | Chief Executive Officer | 62 | 2024-03-24 |
Rick Scalzo
DFI | Director of Finance/CFO | 39 | 2020-06-30 |
Douglas Kerr
CTO | Chief Tech/Sci/R&D Officer | 58 | 2024-09-02 |
Manager | Title | Age | Since |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 61 | 2018-10-31 |
Jason Rhodes
CHM | Chairman | 55 | 2018-10-31 |
Dirk Kersten
BRD | Director/Board Member | 50 | 2018-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-1.00% | -9.50% | -42.50% | +113.34% | 1.42B | ||
-0.77% | -2.20% | +9.84% | +98.50% | 118B | ||
-0.10% | -5.13% | -28.93% | +8.03% | 72.09B | ||
-2.13% | -3.83% | +68.23% | +140.90% | 38.79B | ||
-2.40% | +1.89% | +31.02% | -22.46% | 28.73B | ||
+2.38% | +3.29% | +58.26% | +12.45% | 24.63B | ||
+4.61% | +2.25% | +11.97% | -30.27% | 23.61B | ||
-2.06% | +6.27% | +380.22% | +952.71% | 15.76B | ||
+0.81% | -0.80% | +189.03% | +244.83% | 14.19B | ||
+0.94% | +8.59% | -19.89% | -31.61% | 13.46B | ||
Average | +0.03% | +0.01% | +65.73% | +148.64% | 35.05B | |
Weighted average by Cap. | -0.26% | -1.19% | +36.16% | +99.35% |
2024 * | 2025 * | |
---|---|---|
Net sales | - | - |
Net income | -326M -311M -293M -259M -462M -28.26B -513M -3.49B -1.29B -11.82B -1.22B -1.2B -49.6B | -411M -391M -369M -326M -582M -35.57B -646M -4.39B -1.63B -14.88B -1.54B -1.51B -62.44B |
Net Debt | -616M -586M -553M -488M -873M -53.36B -968M -6.58B -2.44B -22.31B -2.31B -2.26B -93.66B | -492M -468M -442M -390M -697M -42.63B -774M -5.26B -1.95B -17.82B -1.84B -1.81B -74.83B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 13.91 $ | -1.00% | 984,219 |
25-02-13 | 14.05 $ | +0.93% | 1,002,739 |
25-02-12 | 13.92 $ | +2.96% | 1,460,523 |
25-02-11 | 13.52 $ | -6.63% | 1,754,910 |
25-02-10 | 14.48 $ | -5.79% | 1,276,829 |
Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DYN Stock